Publications by authors named "Julianna M Mastrorilli"
Background: Apixaban, rivaroxaban, and warfarin have shown benefit for preventing major ischemic events, albeit with increased bleeding risk, among patients in the general population with atrial fibrillation (AF). However, data are scarce in patients with cirrhosis and AF.
Objective: To compare the effectiveness and safety of apixaban versus rivaroxaban and versus warfarin in patients with cirrhosis and AF.
Article Synopsis
- - The study aimed to compare the safety and effectiveness of warfarin and rivaroxaban against apixaban in patients with atrial fibrillation and advanced chronic kidney disease, addressing a gap in existing head-to-head data.
- - Using data from two nationwide databases, researchers matched cohorts of patients who initiated either warfarin or rivaroxaban against those who began treatment with apixaban, analyzing outcomes over nearly a decade.
- - Results showed that both warfarin and rivaroxaban were associated with higher rates of major bleeding compared to apixaban, while all-cause mortality and ischemic stroke rates were similar between the groups, highlighting apixaban as a potentially safer option.
Background: We aimed to determine whether integrating concepts from the notes from the electronic health record (EHR) data using natural language processing (NLP) could improve the identification of gout flares.
Methods: Using Medicare claims linked with EHR, we selected gout patients who initiated the urate-lowering therapy (ULT). Patients' 12-month baseline period and on-treatment follow-up were segmented into 1-month units.
Importance: The development of an optimal stroke prevention strategy, including the use of oral anticoagulant (OAC) therapy, is particularly important for patients with atrial fibrillation (AF) who are living with dementia, a condition that increases the risk of adverse outcomes. However, data on the role of dementia in the safety and effectiveness of OACs are limited.
Objective: To assess the comparative safety and effectiveness of specific OACs by dementia status among older patients with AF.
Purpose: Because chronic kidney disease (CKD) is often under-coded as a diagnosis in claims data, we aimed to develop claims-based prediction models for CKD phenotypes determined by laboratory results in electronic health records (EHRs).
Patients And Methods: We linked EHR from two networks (used as training and validation cohorts, respectively) with Medicare claims data. The study cohort included individuals ≥65 years with a valid serum creatinine result in the EHR from 2007 to 2017, excluding those with end-stage kidney disease or on dialysis.